Jazz Pharmaceuticals PLC Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Maybe just on JZP-458, can you talk about if you remain confident that we will see interim data in the near term? And just what is the clinical path from here in terms of remaining on track to submit a filing by year-end?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : The Zepzelca number was very impressive in the third quarter. So just provide some more detail on the early feedback from physicians on the product. How they're initially using it in their patients? How much has getting on the NCCN Guidelines helped with uptake? And what is receptivity from payers been on pricing? And how has reimbursement been so far with Zepzelca?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Back to 458, I think it's probably for Rob or for Dan to some degree. I just would like you to -- if you could confirm that all aspects of the 458 development trial are on track? And also, how quickly can you make product? And are you already making product to meet demand? And when can you begin to play offense in terms of looking at additional geographies and indications?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Does that mean you could meet all demand as soon as it's approved?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : For JZP-385, you completed the healthy volunteer study of the modified release formulation. Can you elaborate on the results there? And in particular, are you constant in the safety and tolerability of this molecule now?